Recommendation 2

     

Recommendation 2Produce and implement clinical guidelines and pathways for  testing,  improved diagnosis and management of cCMV.

Paediatricians and other professionals working with families must understand the guidelines for managing CMV so that more families receive monitoring and support. 

As the estimated costs for acute antiviral treatment are relatively minor, more research needs to be conducted to assess whether antiviral treatment can be effective in preventing or reducing the severity of other forms of impairment that develop as a consequence of cCMV.

There is evidence to show that the antiviral medicine valganciclovir is effective at reducing SNHL, as well as developmental delays in other neurocognitive functions, in the 24 months following birth.

Given that a high proportion of the cost burden is attributable to babies born without symptoms, who later develop neurodevelopmental impairments. More research into the benefits of this treatment in babies presenting with no symptoms may provide another avenue from which to target the cost burden of the virus.  It is only through this that we will be able to bring the UK in line with other countries more advanced in managing CMV infection. 

 

     

Our Stories

April 2011 Lydia is one of non-identical twins, born on 6th April 2011 at 38 weeks in Welwyn Garden City with her brother Isaac.   Lydia was very small at 1.8kg (3lb15oz) so she... Read more
December 1997 Lewis was born 3 weeks early on 23rd December 1997 following a normal healthy pregnancy. The labour was not easy, but relatively quick being 4 hours in total but he was... Read more

Latest Events

Registered charity no: 1171773